Severe post-thrombotic syndrome (PTS)isresponsible forconsiderabled isability,reduced quality of lifea nd increasedh ealth carec osts. Currentt herapies arel imited and often ineffective. We performedatwo-centre,randomized,cross-over controlled trial to evaluate Venowave TM ,anovell ower-limb venous-return assist device,for thet reatment of severe PTS. Eligible subjects were allocatedt or eceive,i nr andomized order, Venowave for eight weeks and ac ontrold evice fore ight weeks.The eightweek treatment periodswereseparatedbyafour-week period whenn od evice was used (i.e.wash-out period).The primary outcome measurewas a'clinical success' defined as:i)reported benefitf romt he device;and ii) moderate or greateri mprovement in symptoms of PTS; andiii) willingness to continue using the device.Secondaryoutcomemeasuresincluded quality of life (QOL) as measured by VEINES-QOL questionnaire (higher scores indicate better QOL), and PTSseverity as measured by Keywords Ve nous thrombosis,clinical studies,deep vein thrombosis the Villalta PTSscale (higherscores indicate more severe PTS). Thes tudy was registeredw ith ClinicalTrials.gov (NCT00182208). Thirty-twop atientsw eree nrolled. Of these, 26 (80%) were also usingg raduatedc ompression stockings. Tw enty-six participants completedb oth trial periods. Clinical success occurred in 10 (31%) participants receiving Venowave and four (13%) participants receivingt he control device,with two(6%)participantsreportingaclinical success with both devices( P=0.11). Mean VEINES-QOL score at thee nd of study periodwas significantlygreater(P=0.004) forVenowave (52.5;SD 5.8) compared to control (50.2;SD 6.2).MeanVillalta scale score at theend of study periodwas significantlydecreased(P=0.004) for Venowave (12.2; SD 6.3) compared to control (15.0; SD 6.1). In conclusion,Venowave appearstobeavery promising newtherapyfor patientswith severe PTS, which maybeusedalone or in combinationwith graduated compression stockings.
Introduction
Post-thrombotic syndrome (PTS) is the most frequent chronic complication of deep vein thrombosis (DVT) of the leg ( 1, 2) . Characterised by pain and swelling, it is responsiblefor considerable personal disability,r educed quality of lifea nd substantial health care costs (estimated at US $250 million per year in North America) (3) (4) (5) (6) (7) (8) . Management of severe PTSpresents aparticularc hallenge to clinicians (5) .T he cornerstone of therapyi s graduated compression stockings whichhaveconsiderableclinical limitations,inthat patients frequentlyexperienceonlypartial or no symptom relief from stockings (5, (9) (10) (11) . Although pneumatic compression pumps can provide symptomatic relief for patients with severe PTS, theiru se is often impractical as patients must remainstationary for twohours or more per day, and the expense of the pumps is oftenprohibitive (12) .
There is aneed to develop effectivetreatmentsfor severe PTS that are well-tolerated and allow patients to carryonwith their dailyactivities (6) . In this clinicaltrial, we evaluate anovel device, Ve nowave TM , for the treatment of severe PTS.
Methods
We performed arandomized placebo-controlled, double-blinded 'cross-over' trialo fp atients with severe PTSa tt wo Clinical Centres (Hamilton Health Sciences,ChedokeDivision,Hamilton, Ontario; and the ThrombosisU nit, SirM ortimer B. Davis JewishG eneral Hospital, Montreal,Q uébec).The clinicalt rial protocol wasa pprovedb yH ealth Canada (No. 64844) and the Research and Ethics Boards of both Clinical Centres.The study wasregistered with ClinicalTrials.gov (NCT00182208) and conducted according to the ICH-Good Clinical Practiceguidelines for clinicaltrials.
Intervention
Ve nowave is abattery-powered lowerlimb venous returnassist devicedeveloped by Saringer Research Incorporated,Stouffville,ON, Canada (Fig. 1) .Itconsistsofarotating motor coupled with awave-generating linkage to aplanarplastic sheet,which is placed longitudinallyonthe posterior aspect of the calf and generatesawave-formmotion on aflexible flat metalplatform. This peristaltic pump (1 cm amplitude,8c mw ide sinusoidal wave moving at 2cm/sec) results in an upward,volumetric displacement of the wave at 16 cc/sec. It is attached firmly aroundthe calf with av elcro supportcuffand maybew ornw hen mobile. The cuffisadjustable to fitdifferent legsizes and can be adjustedto accommodate changes in legswelling. Ve nowave is designed to counteract venous stasis and venous hypertension, etiological factorsr esponsible for the development of PTS (13) . In ap reviousstudy of 10 subjectswith chronic limb edema, we demonstratedthat wearing Ve nowave for50minutes(min) produced an 88%increase in duplexultrasound-detected venous flowatthe common femoralvein(p=0.03) (13) .Inasubsequent open-label pilot study (14) ,w ed emonstrated that Ve nowave resultedi na substantial clinical improvement of symptoms in four of six subjects with severe PTS (14) .
All components of the control and active deviceswere identical,except for the connection betweenthe motor and the planar sheetw as inactiveinthe control device.Therefore,t he control device wasidenticalinsize, weight and sound to the activeintervention butdid not generate awaveform motion.The control device produced some calf compression through addedp ressure from the cuff, and wastherefore presentedtothe participants as one of twoactiveinterventions and not as aplacebo.
Participants
Subjectsover18years of age with PTS were potentiallyeligible if theyhad: i) aprevioushistoryofobjectively-documented deep vein thrombosis; ii) dailyleg swelling with discomfort(i.e.reported at leasto ne of the following symptoms: heavy legs, aching legs and/or throbbing) for aminimum of 6months that was consideredd ue to PTS;a nd iii)V illalta scales coreo fg reater than14(i.e.corresponds to severe PTS) (15) .
Anypatients whohad: i) unstablesymptoms(worsening, improving or variable over the previous month); ii) chronic lower limb edemafrom causes other thandeep vein thrombosis; iii) active venous ulceration; iv)b aseline calfc ircumference greater than40cm(cuffistoo small); v) symptomatic peripheral arterial disease; or vi) peripheral neuropathy, were excluded. Current or prior useo fg raduated compression stockings did not influence eligibility.
Eligible,c onsenting subjects were allocated randomly in a 1:1 ratiotofolloweitherSequence 'A'(Ve nowave for8weeks in Period 1f ollowedb yc ontrol for 8w eeks in Period 2), or Sequence 'B'(control for 8w eeks in Period 1f ollowedb yVe nowave for8weeks in Period 2). At the end of Period 1, participants hadafour-weekwash-outperiod beforestarting Period 2.
Devices were pre-packaged in pairsw ith each Ve nowave paired with acontrol device.Paired devices were labeled"A" and "B" corresponding to theorder of use, and notrelated to whether theywere activeorcontrol. Random allocation wasdetermined by consecutivelynumbered patient kits that contained encrypted codes, corresponding to arandomly orderedpairofVe nowave or control device. Upon obtaining writteni nformed consent from an eligible participant, the researchnurse openedthe next patient kit in the sequence and provided the subjectwith deviceA.Participants were provided with deviceBat the end of the wash-out period.
All participants were instructedt op ut the deviceo ne ach morning andtowear it for most of the day, for the duration of the studyperiod. Therewas no restriction (upperlimit) on the duration of use. Subjectswereinformedthatthe devicecould be worn when theywerestationaryormobile andweretaught howtouse the de- vicei .e.m ethod of application to leg, insertion of batteries,e tc. They were also giveninstructions on maintenanceofthe device, andcontact numbers in the eventofamalfunction. Thedevicewas to be worn onlyonthe legexhibiting the PTS (i.e.the indexleg).
Study subjects, investigatorsa nd researchn ursesw ere blindedtotreatment allocation. To help maintain blinding, study participants were assessed at differentt imest oe ach other and were asked nottodiscuss issuesrelating to the mechanical operation of the devicewith their clinicians. Both devices were called 'Ve nodevice'rather than Ve nowave, to avoid potential insights into the mechanism of action of the intervention.
Study measures
Four measurement instruments were used in this study. Aglobal rating instrument wasusedtodetermine if each treatment phase wasassociatedwith a'clinical success' (Fig. 2) .Similaroutcome measuresh aveb een used in twop reviousr andomized trials in subjectsw ith PTS (11,1 2). The Villalta scalew as used to measurethe severity of PTS at baseline (inclusion criterion)and follow-up, and wasasecondaryo utcome measure (15) .T his scale wasdesignedtodiagnose and ratethe severity of PTS by quantifying five symptoms and six signs and has been used frequently in studiesofpatients with PTS. Higherscores indicate moresevere PTSand ascoreofgreater than14corresponds to severe PTS( maximum scoreo f3 3) (15) .A lthough both legs were assessed,onlythe scores for the indexleg were used in the analysis. TheVEINES-QOL questionnaire wasusedtomeasure quality of life(QOL) (16) . VEINES-QOL, avenous disease-specificquality of life instrument, hasbeen shown to be reliable and responsivet oc hange over time in patients with PTS (16,1 7). VEINES-Sym is av alidateds ubscale of VEINES-QOLt hat measuresseverity of venous symptoms. ForVEINES-QOL and VEINES-Sym, higher scoresi ndicate better quality of life. At study end,p articipants were asked if theyp referred the 'treatment intervention' in Period 1orPeriod 2.
Data collection and follow-up
All data were submittedt ot he data-coordinating centre within the Clinical Trials Methodology Group,H enderson Research Centre, Hamilton, ON,Canada. They were responsiblefor maintaining the concealment of the random allocation sequence from investigatorsand patients. The study design, analyses, and decision to publish were all determinedbythe investigators.
Study participants were scheduledt oa ttend fourv isits: 1) baseline;2)at8w eeks (prior to cross-over); 3) at 12 weeks (after the 4-week 'wash-out'period); and 4) at 20 weeks.The Villalta Scale and VEINESquestionnaire were completed at all visits. TheGlobalRating Instrument wasadministeredatthe eight and 20 week follow-up visits; thati s, at the end of each study period.Study participants were alsoasked to keep adiary of the number of hours theyusedthe device each day.
Participants were screened clinicallyf or recurrent venous thromboembolism and the development of venous ulceration at each visit. Adverse clinicalevents were adjudicated by ablinded expertinThrombosis medicine.Seriousadverse eventswere reported to Health Canada and the Research and Ethics Boards of both centres.
Outcomes
The primaryoutcome was'clinical success' defined as fulfilling all of the following criteria:1)the patient reported benefitfrom the intervention; 2) experienced at least moderate improvement in symptoms of PTS; and 3) waswilling to continue to use the device (Fig. 2) . Secondary outcome measuresincludedeach of the componentc linical successr esponses,d evicep reference, PTS severity (Villalta Scale score), venous disease-specific quality of life (VEINES-QOL) and severity of venous lowerl imb symptoms (VEINES-Sym).
Statisticalanalysis
Sample size wasc alculated fort he primaryb inary outcome measure.From ourpreliminary pilot study (14) ,weestimateda probability of clinicalsuccess with the active device of 67% in subjects with severe PTS. Basedo np reviousr esearch in this field, we expectaplacebo effect of approximately 20%. We consideredaminimum clinically important difference to be an additionalabsoluteprobability of clinical successof40%, that is a probability of clinicalsuccess of 60% of clinicalsuccess with the active device (Chi 2 =0.05, two-sided; power=80%). Taking into account loss to follow-up (10%), we required atotal sample size of 32 subjects.
The paired binaryo utcomes were analyzed primarily using McNemar'stests, and secondly, using logistic mixed models to account for correlation and period effects, and also to assess the impact of potentiallyi nfluential baseline covariates:g ender, body mass index( BMI), education,s welling, compression stockings use.The paired continuous outcome measures(Villalta and VEINESs cales cores)w ere analyzed primarily using paired t-tests, and secondly, using linear mixed models to account for correlation, baseline scores and aperiod effect,and an extendedmodel adding the covariates listedabove.P-values less than0.05 were considered to be statistically significant. All statisticala nalyses were performed using SAS version 9.1( Cary, NC,USA).
Results
Between February2004 and October 2005, 32 patients were recruited. Thebaseline characteristics of participants are presented in Table1.Mean age was50years,and 50% were women. Most (80%) participants were using graduated compression stockings at the time of recruitment. Twenty-six participants completed the trial (Fig. 2) . Threeparticipants withdrew during Period 1(one patient died,two experienced side effects possibly related to the device), twowithdrew during the wash-out period (one suffered from depression, one withdrew to provide care to an ill spouse), and onepatient withdrew during Period 2(experienced side effects possibly related to the device) (see Adverse Events) (Fig. 3) Meanduration of use (perday)was 6.2hours (h) (SD 3.4) for Venowave and 5.3h(SD 3.1) for control.
Clinical success
Aclinical successwas reportedin10participants usingtheVe nowave device, and in fourpatients usingthe control device;two of these participants reported aclinical successwith both devices (p=0.11).Inthe twopatients whoreported aclinical successwith both devices,one had apreference for Ve nowave and oneapreference for control. Fourteenparticipants (54%) didnot reporta clinical successtoeitherdevice(Table2). Graduated compression stockings were worn by five of the eight participants whoreported aclinical successwith Ve nowave alone, and in allparticipants whoreported eitheraclinical successwith the control devicealone (n=2) or with both devices (n=2). Thelogistic modeling of clinical successp roduced stronger treatment effects (p=0.068 forthe multivariable modeladjusting for period effect and baseline covariates), buts howedn oe videnceo fp eriod or baseline covariate main effects.
Secondaryoutcomes
Table2also presentsasummaryand analysis of the components defining clinicals uccess, and patient device preference.T he trend in favorofVe nowave wasconsistent across all threecomponents; however, onlythe "benefit" component showedastrong treatment effect.Therewas anon-significant benefitassociated with Ve nowave forthe composite outcome of "benefit" from the device and willing to "continue to use" the device,r eported in half of the participants using Ve nowave.N ineteen participants preferred the Ve nowave while onlyfour preferred the control device; three preferred neither(P=0.003).
The VEINES questionnaire and Villalta scalew ere completed fullyatall fourfollow-up assessments by 24 and 25 participants respectively.M ean VEINES-QOL score at thee nd of study period wass ignificantly greater (P=0.004)f or Ve nowave (52.5; SD 5.8) compared to control (50.2;SD6.2). MeanVillalta scalescoreatthe end of study period wassignificantly reduced for Ve nowave (12.2; SD 6.3) compared to control (15.0;SD6.1); p=0.004 (seeTable 3).After adjustment for baseline scores, period effect and baseline covariates in the mixed model, allt reatment effect analyses remained consistent with the results of the pairedt-tests. There wasnoevidenceofa"carry-over" effect for anyoutcome measure. Left leg withPTS -n(%) 026 0(81)
Adverse events
One patient died during week 8(control deviceperiod). Thepatient did not completePeriod 1and wasnot wearing the deviceat the time of death. Causeofdeathwas deemed to be cardiacand unrelated to the study.The patient did not have an autopsy,but the case wasreviewedbythe localCoroner. Clinical details were alsop resentedt ot he localR esearch and Ethics Boards and HealthCanadaand determinedtobeunrelated to the study device.N oc ases of recurrent venous thromboembolism were reported. Oneparticipant withdrew from the trialbecauseofactive venous ulceration that occurredafter aminor injurywhile wearing the control device. He discontinuedwearing the deviceafter the injury, and the small area of ulceration wasattributedtothe injuryand wasdeemed to be unrelated to the studydevice. Three other participants reported side-effects, deemed to be 'non-serious' and related or possibly related to the device. Allthreeparticipants withdrew from the trial. Oneparticipant reported 'leg swelling, irritation and superficialbleeding', onereported 'skin irritation' and onereported 'leg swelling with itching of skin'. (1) and (2) and (3). §Composite of outcomes (1) and (3). *McNemar'stest.
Discussion
In this randomized controlledtrial of patients with severe PTS, almost 40% of patients treated with Ve nowave reportedameaningful clinical response. In addition, there wasastatistically significant improvement in severity of PTS and venous disease-specific quality of life with Ve nowave treatment compared to control. Thec hange in VEINES-QOLa nd VEINES-Sym scores with Ve nowave in our studyare similartothe clinicalchange observedi nap rospectivec ohorts tudy of patients with symptomatic improvement after acuteD VT (between 1and 4months) (17).
Although not statisticallys ignificant fort he primaryc ompositeoutcome, we believe thatthese findings areofconsiderable clinicalimportance. Severe PTSisresponsible for substantialpersonal disability,work absenteeism,reduced quality of life and increased health care costs (3) (4) (5) (6) (7) (8) . Them ainstayo fc urrent therapy, graduated compression stockings, is often of limited benefit in patients with severe PTS (11) . In this study,most patients were using compression stockings at the time of recruitment butcontinued to have severe symptoms despite their use. Importantly,most patients whoreported abenefit withVe nowave were alsou sing graduated compression stockings concomitantly. Therefore, Ve nowave can be used aloneorinconjunction with graduated compression stockings. Compared with pneumatic compression pumps (12) , Ve nowave allowedpatients to remain mobile,a nd the device improved, rather thani nterfered with, activities of dailyactivitiesduring use.
Ve nowave appears to be safe. Themost common side-effects attributedtoVe nowave were heat sensation, skin irritation and increased sweating. No cases of recurrent venous thromboembolism were reported during the studyperiod.However,sincethis wasasmall study,and the duration of follow-up in this trial was limitedtoeight weeks,further prospective studiesare required to determine the long-termsafetyand tolerability of Ve nowave.
Although everye ffortw as made to maintain blindingo f study participants and research nurses,i ti sl ikelyt hat participants were aware of adifference between the activeand control devices, giventhe mechanical natureofthe intervention. In addition to aplacebo effect,weexpected the control device to have an activec omponent, namely added legc ompression with planar calf supportd uring standing and walking.W e, therefore, presented the control deviceasanalternative'active' device rather thanplacebo.F our participants reported aclinical successwith the control device, twoofwhich also had aclinical successwith Ve nowave.Our choiceofcontrol device would be expected to increase the likelihood of not finding atreatment effect when one trulyexisted (i.e.type II error), undermining our ability to detect astatistically significant benefitwith Ve nowave.
Themainlimitations of our studyare the small sample size and shortduration of follow-up. Thatsaid, this studyisthe largest clinicalt rial of treatment of severe PTS. Further studies are required to determine the longer-termbenefits and safety of Venowave.S trengths of the studya re thatp articipants, investigators, assessorsa nd data analyzers were all blindeda nd that validatedscales were used to assess clinical outcomes.
In conclusion, Ve nowave appears to be averypromising new therapyf or severe PTS, ac hronic disabling condition with limited treatment options.Inour study population of patients with severe PTS, refractory to standard therapies, almost40% of patients reported clinicalimprovement with Ve nowave.
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